{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:36Z","timestamp":1791232476502,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1038\/nrc1120","type":"journal-article","created":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T10:30:10Z","timestamp":1057055410000},"page":"517-525","source":"Crossref","is-referenced-by-count":170,"title":["Curing metastatic cancer: lessons from testicular germ-cell tumours"],"prefix":"10.1038","volume":"3","author":[{"given":"John R.W.","family":"Masters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"K\u00f6berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrc1120_CR1","unstructured":"Souhami, R. & Tobias, J. Cancer and its Management 3rd edn (Blackwell Science, Oxford, 1998)."},{"key":"BFnrc1120_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ijc.1440","volume":"94","author":"DM Parkin","year":"2001","unstructured":"Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153\u2013156 (2001).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJM199707243370406","volume":"337","author":"GJ Bosl","year":"1997","unstructured":"Bosl, G. J. & Motzer, R. J. Testicular germ-cell cancer. N. Engl. J. Med. 337, 242\u2013253 (1997). A clearly written review that summarizes most of the clinical aspects of TGCTs.","journal-title":"N. Engl. J. Med."},{"key":"BFnrc1120_CR4","first-page":"1996","volume":"48","author":"GB Pierce","year":"1988","unstructured":"Pierce, G. B. & Speers, W. C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 48, 1996\u20132004 (1988).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR5","first-page":"6","volume":"70","author":"S Sell","year":"1994","unstructured":"Sell, S. & Pierce, G. B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinoma and epithelial cancers. Lab. Invest. 70, 6\u201322 (1994).","journal-title":"Lab. Invest."},{"key":"BFnrc1120_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0305-7372(76)80009-6","volume":"3","author":"ML Samuels","year":"1976","unstructured":"Samuels, M. L., Lanzotti, V. J., Holoye, P. Y., Boyle, L. E. & Johnson, D. E. Combination chemotherapy in germinal cell tumors. Cancer Treat. Rev. 3, 185\u2013204 (1976).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrc1120_CR7","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1073\/pnas.072067999","volume":"99","author":"LH Einhorn","year":"2002","unstructured":"Einhorn, L. H. Curing metastatic testicular cancer. Proc. Natl Acad. Sci. USA 99, 4592\u20134595 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1120_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/0003-4819-87-3-293","volume":"87","author":"LH Einhorn","year":"1977","unstructured":"Einhorn, L. H. & Donohue, J. Cis-diamminedicloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87, 293\u2013298 (1977). The landmark clinical study that demonstrated that TGCTs are curable with cisplatin.","journal-title":"Ann. Intern. Med."},{"key":"BFnrc1120_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ijc.2910340123","volume":"34","author":"JW Oosterhuis","year":"1984","unstructured":"Oosterhuis, J. W., Andrews, P. W., Knowles, B. B. & Damjanov, I. Effects of cis-platinum on embryonal carcinoma cell lines in vitro. Int. J. Cancer 34, 133\u2013139 (1984).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR10","first-page":"213","volume":"79","author":"MC Walker","year":"1987","unstructured":"Walker, M. C., Parris, C. N. & Masters, J. R. W. Differential sensitivities to chemotherapeutic drugs between testicular and bladder cancer cells. J. Natl Cancer Inst. 79, 213\u2013216 (1987).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc1120_CR11","first-page":"6810","volume":"47","author":"MF Pera","year":"1987","unstructured":"Pera, M. F., Friedlos, F., Mills, J. & Roberts, J. J. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res. 47, 6810\u20136813 (1987).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR12","first-page":"6592","volume":"51","author":"AM Fry","year":"1991","unstructured":"Fry, A. M. et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51, 6592\u20136595 (1991).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/09553008814550921","volume":"53","author":"CN Parris","year":"1988","unstructured":"Parris, C. N., Arlett, C. F., Lehmann, A. R., Green, M. H. L. & Masters, J. R. W. Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. Int. J. Radiat. Biol. 53, 599\u2013608 (1988).","journal-title":"Int. J. Radiat. Biol."},{"key":"BFnrc1120_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/35043102","volume":"1","author":"JR Masters","year":"2000","unstructured":"Masters, J. R. Human cancer cell lines: fact and fantasy. Nature Rev. Mol. Cell Biol. 1, 233\u2013236 (2000).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrc1120_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrc775","volume":"2","author":"JR Masters","year":"2002","unstructured":"Masters, J. R. HeLa cells 50 years on: the good, the bad and the ugly. Nature Rev. Cancer 2, 315\u2013319 (2002).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc1120_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/bjc.1996.200","volume":"73","author":"RA Olie","year":"1996","unstructured":"Olie, R. A. et al. Apoptosis of human seminoma cells upon disruption of their microenvironment. Br. J. Cancer 73, 1031\u20131036 (1996).","journal-title":"Br. J. Cancer"},{"key":"BFnrc1120_CR17","first-page":"7513","volume":"50","author":"CN Parris","year":"1990","unstructured":"Parris, C. N., Walker, M. C., Masters, J. R. W. & Arlett, C. F. Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. Cancer Res. 50, 7513\u20137518 (1990).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR18","doi-asserted-by":"publisher","first-page":"14298","DOI":"10.1073\/pnas.162491399","volume":"99","author":"S Ishida","year":"2002","unstructured":"Ishida, S., Lee, J., Thiele, D. J. & Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl Acad. Sci. USA 99, 14298\u201314302 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1120_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/bjc.1995.135","volume":"71","author":"MWJ Sark","year":"1995","unstructured":"Sark, M. W. J. et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br. J. Cancer 71, 684\u2013690 (1995).","journal-title":"Br. J. Cancer"},{"key":"BFnrc1120_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/0959-8049(96)00033-0","volume":"32A","author":"JRW Masters","year":"1996","unstructured":"Masters, J. R. W. et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur. J. Cancer 32A, 1248\u20131253 (1996).","journal-title":"Eur. J. Cancer"},{"key":"BFnrc1120_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D","volume":"85","author":"C Meijer","year":"2000","unstructured":"Meijer, C. et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int. J. Cancer 85, 777\u2013781 (2000).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR22","volume-title":"Inherent Sensitivity and Acquired Resistance in Human Testicular Germ Cell Tumours In Vitro","author":"MC Walker","year":"1990","unstructured":"Walker, M. C. Inherent Sensitivity and Acquired Resistance in Human Testicular Germ Cell Tumours In Vitro. PhD Thesis, Univ. London (1990)."},{"key":"BFnrc1120_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G","volume":"70","author":"B K\u00f6berle","year":"1997","unstructured":"K\u00f6berle, B. et al. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer 70, 551\u2013555 (1997).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A","volume":"73","author":"H Burger","year":"1997","unstructured":"Burger, H., Nooter, K., Boersma, A. W. M., Kortland, C. J. & Stoter, G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int. J. Cancer 73, 592\u2013599 (1997).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR25","first-page":"2446","volume":"56","author":"EH Richards","year":"1996","unstructured":"Richards, E. H., Hickey, E., Weber, L. & Masters, J. R. W. Effects of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res. 56, 2446\u20132451 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/bjc.1995.383","volume":"72","author":"EH Richards","year":"1995","unstructured":"Richards, E. H., Hickman, J. A. & Masters, J. R. W. Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br. J. Cancer 72, 620\u2013626 (1995).","journal-title":"Br. J. Cancer"},{"key":"BFnrc1120_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<800::AID-IJC8>3.0.CO;2-V","volume":"67","author":"JVE Hettinga","year":"1996","unstructured":"Hettinga, J. V. E. et al. Heat-shock protein expression in cisplatin-sensitive and-resistant human tumor cells. Int. J. Cancer 67, 800\u2013807 (1996).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/362847a0","volume":"362","author":"SW Lowe","year":"1993","unstructured":"Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847\u2013849 (1993).","journal-title":"Nature"},{"key":"BFnrc1120_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957\u2013967 (1993).","journal-title":"Cell"},{"key":"BFnrc1120_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nm0796-804","volume":"2","author":"SG Lutzker","year":"1996","unstructured":"Lutzker, S. G. & Levine, A. J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med. 2, 804\u2013810 (1996).","journal-title":"Nature Med."},{"key":"BFnrc1120_CR31","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1038\/sj.onc.1204394","volume":"20","author":"SG Lutzker","year":"2001","unstructured":"Lutzker, S. G., Mathew, R. & Taller, D. R. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 20, 2982\u20132986 (2001).","journal-title":"Oncogene"},{"key":"BFnrc1120_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.2002.20.6.1551","volume":"20","author":"AMF Kersemaekers","year":"2002","unstructured":"Kersemaekers, A. M. F. et al. Role of p53 and MDM2 in treatment response of human germ cell tumors. J. Clin. Oncol. 20, 1551\u20131561 (2002). A comprehensive analysis of the role of p53 in germ-cell tumours in relation to both cisplatin sensitivity and cisplatin resistance, plus a helpful review of p53 expression and some  in vitro  data.","journal-title":"J. Clin. Oncol."},{"key":"BFnrc1120_CR33","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1038\/sj.onc.1201770","volume":"16","author":"J Houldsworth","year":"1998","unstructured":"Houldsworth, J. et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16, 2345\u20132349 (1998).","journal-title":"Oncogene"},{"key":"BFnrc1120_CR34","first-page":"4285","volume":"57","author":"PM O'Connor","year":"1997","unstructured":"O'Connor, P. M. et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285\u20134300 (1997).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.0.CO;2-S","volume":"81","author":"AM Burger","year":"1999","unstructured":"Burger, A. M. et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int. J. Cancer 81, 620\u2013628 (1999).","journal-title":"Int. J. Cancer"},{"key":"BFnrc1120_CR36","first-page":"1391","volume":"59","author":"JM Brown","year":"1999","unstructured":"Brown, J. M. & Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391\u20131399 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR37","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1073\/pnas.95.11.6163","volume":"95","author":"DB Zamble","year":"1998","unstructured":"Zamble, D. B., Jacks, T. & Lippard, S. J. p53-dependent and-independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl Acad. Sci. USA 95, 6163\u20136168 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1120_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ng0398-202","volume":"18","author":"RE Braun","year":"1998","unstructured":"Braun, R. E. Every sperm is sacred \u2014 or is it? Nature Genet. 18, 202\u2013204 (1998).","journal-title":"Nature Genet."},{"key":"BFnrc1120_CR39","first-page":"1834","volume":"56","author":"CM Chresta","year":"1996","unstructured":"Chresta, C. M., Masters, J. R. W. & Hickman, J. A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 56, 1834\u20131841 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR40","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/sj.onc.1202420","volume":"18","author":"EL Arriola","year":"1999","unstructured":"Arriola, E. L., Rodriguez-Lopez, A. M., Hickman, J. A. & Chresta, C. M. Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 18, 1457\u20131464 (1999).","journal-title":"Oncogene"},{"key":"BFnrc1120_CR41","first-page":"513","volume":"63","author":"T Mueller","year":"2003","unstructured":"Mueller, T. et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res. 63, 513\u2013521 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR42","first-page":"767","volume":"9","author":"F Mayer","year":"2003","unstructured":"Mayer, F. et al. Molecular determinants of treatment response in human germ cell tumors. Clin. Cancer Res. 9, 767\u2013773 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc1120_CR43","first-page":"4881","volume":"56","author":"D Fink","year":"1996","unstructured":"Fink, D. et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881\u20134886 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1074-5521(96)90149-0","volume":"3","author":"JA Mello","year":"1996","unstructured":"Mello, J. A., Acharya, S., Fishel, R. & Essigmann, J. M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol. 3, 579\u2013589 (1996).","journal-title":"Chem. Biol."},{"key":"BFnrc1120_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1568-7864(02)00187-8","volume":"2","author":"A Massey","year":"2003","unstructured":"Massey, A., Offman, J., Macpherson, P. & Karran, P. DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells. DNA Repair 2, 73\u201389 (2003).","journal-title":"DNA Repair"},{"key":"BFnrc1120_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1074-5521(00)00064-8","volume":"7","author":"ZZ Zdraveski","year":"2000","unstructured":"Zdraveski, Z. Z., Mello, J. A., Marinus, M. G. & Essigmann, J. M. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 7, 39\u201350 (2000).","journal-title":"Chem. Biol."},{"key":"BFnrc1120_CR47","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1128\/MCB.21.8.2858-2866.2001","volume":"21","author":"M Takata","year":"2001","unstructured":"Takata, M. et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol. Cell. Biol. 21, 2858\u20132866 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc1120_CR48","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1021\/bi000130k","volume":"39","author":"A Vaisman","year":"2000","unstructured":"Vaisman, A., Masutani, C., Hanaoka, F. & Chaney, S. G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase \u03b7. Biochemistry 39, 4574\u20134580 (2000).","journal-title":"Biochemistry"},{"key":"BFnrc1120_CR49","first-page":"2220","volume":"61","author":"KA Robertson","year":"2001","unstructured":"Robertson, K. A. et al. Altered expression of Ape1\/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 61, 2220\u20132225 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR50","first-page":"4899","volume":"62","author":"T Furuta","year":"2002","unstructured":"Furuta, T. et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62, 4899\u20134902 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR51","first-page":"3019","volume":"48","author":"P Bedford","year":"1988","unstructured":"Bedford, P., Fichtinger-Schepman, A. M., Walker, M. C., Masters, J. R. W. & Hill, B. T. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res. 48, 3019\u20133024 (1988). The first indication that NER was defective in TGCT cells.","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR52","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/0959-8049(94)90301-8","volume":"30A","author":"BT Hill","year":"1994","unstructured":"Hill, B. T. et al. Deficient repair of cisplatin-DNA adducts in human testicular teratoma cell lines established from tumours from untreated patients. Eur. J. Cancer 30A, 832\u2013837 (1994).","journal-title":"Eur. J. Cancer"},{"key":"BFnrc1120_CR53","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0006-2952(96)00549-7","volume":"52","author":"B K\u00f6berle","year":"1996","unstructured":"K\u00f6berle, B., Payne, J., Grimaldi, K., Hartley, J. & Masters, J. R. W. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by Q-PCR. Biochem. Pharmacol. 52, 1729\u20131734 (1996).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc1120_CR54","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/nar\/23.9.1604","volume":"23","author":"AD Baxevanis","year":"1995","unstructured":"Baxevanis, A. D. & Landsman, D. The HMG-1 box protein family: classification and functional relationships. Nucleic Acids Res. 23, 1604\u20131613 (1995).","journal-title":"Nucleic Acids Res."},{"key":"BFnrc1120_CR55","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/21460","volume":"399","author":"UM Ohndorf","year":"1999","unstructured":"Ohndorf, U. M., Rould, M. A., He, Q., Pabo, C. O. & Lippard, S. J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399, 708\u2013712 (1999). A key study showing the recognition of cisplatin-damaged DNA by high mobility group proteins.","journal-title":"Nature"},{"key":"BFnrc1120_CR56","doi-asserted-by":"publisher","first-page":"10394","DOI":"10.1073\/pnas.91.22.10394","volume":"91","author":"JC Huang","year":"1994","unstructured":"Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J. & Sancar, A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl Acad. Sci. USA 91, 10394\u201310398 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc1120_CR57","doi-asserted-by":"publisher","first-page":"10004","DOI":"10.1021\/bi960453+","volume":"35","author":"DB Zamble","year":"1996","unstructured":"Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A. & Lippard, S. J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004\u201310013 (1996).","journal-title":"Biochemistry"},{"key":"BFnrc1120_CR58","doi-asserted-by":"publisher","first-page":"14807","DOI":"10.1021\/bi9717643","volume":"36","author":"UM Ohndorf","year":"1997","unstructured":"Ohndorf, U. M., Whitehead, J. P., Raju, N. L. & Lippard, S. J. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry 36, 14807\u201314815 (1997).","journal-title":"Biochemistry"},{"key":"BFnrc1120_CR59","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1021\/bi971675q","volume":"37","author":"EE Trimmer","year":"1998","unstructured":"Trimmer, E. E., Zamble, D. B., Lippard, S. J. & Essigmann, J. M. Human testis-determining factor SRY binds to the major adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry 37, 352\u2013362 (1998).","journal-title":"Biochemistry"},{"key":"BFnrc1120_CR60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0162-0134(02)00472-5","volume":"91","author":"DB Zamble","year":"2002","unstructured":"Zamble, D. B., Mikata, Y., Eng, C. H., Sandman, K. E. & Lippard, S. J. Testis-specific HMG-domain protein alters the responses of cells to cisplatin. J. Inorg. Biochem. 91, 451\u2013462 (2002).","journal-title":"J. Inorg. Biochem."},{"key":"BFnrc1120_CR61","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/labinvest.3780302","volume":"81","author":"H Stoop","year":"2001","unstructured":"Stoop, H. et al. Reactivity of germ cell maturation stage-specific markers in spermatocytic seminoma: diagnostic and etiological implications. Lab. Invest. 81, 919\u2013928 (2001).","journal-title":"Lab. Invest."},{"key":"BFnrc1120_CR62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","volume":"9","author":"B K\u00f6berle","year":"1999","unstructured":"K\u00f6berle, B., Masters, J. R. W., Hartley, J. A. & Wood, R. D. Reduced repair of cisplatin-induced DNA damage in testicular germ cell tumours due to a specific protein defect. Curr. Biol. 9, 273\u2013276 (1999). First unequivocal proof that NER is defective in TGCTs (earlier studies had used assays that required supralethal concentrations of cisplatin).","journal-title":"Curr. Biol."},{"key":"BFnrc1120_CR63","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/nar\/28.2.402","volume":"28","author":"SL Chew","year":"2000","unstructured":"Chew, S. L., Baginsky, L. & Eperon, I. C. An exonic splicing silencer in the testis-specific DNA ligase III beta exon. Nucleic Acids Res. 28, 402\u2013410 (2000).","journal-title":"Nucleic Acids Res."},{"key":"BFnrc1120_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0921-8777(00)00073-2","volume":"485","author":"JE Cleaver","year":"2001","unstructured":"Cleaver, J. E., Karplus, K., Kashani-Sabet, M. & Limoli, C. L. Nucleotide excision repair 'a legacy of creativity'. Mutat. Res. 485, 23\u201336 (2001).","journal-title":"Mutat. Res."},{"key":"BFnrc1120_CR65","first-page":"634","volume":"3","author":"IA Cree","year":"2002","unstructured":"Cree, I. A., Knight, L., di Nicolantonio, F., Sharma, S. & Gulliford, T. Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr. Opin. Invest. Drugs 3, 634\u2013640 (2002).","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"BFnrc1120_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1470-2045(03)00959-8","volume":"4","author":"MR Middleton","year":"2003","unstructured":"Middleton, M. R. & Margison, G. P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 4, 37\u201344 (2003).","journal-title":"Lancet Oncol."},{"key":"BFnrc1120_CR67","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/carcin\/21.3.453","volume":"21","author":"J de Boer","year":"2000","unstructured":"de Boer, J. & Hoeijmakers, J. H. J. Nucleotide excision repair and human syndromes. Carcinogenesis 21, 453\u2013460 (2000).","journal-title":"Carcinogenesis"},{"key":"BFnrc1120_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/35094000","volume":"1","author":"EC Friedberg","year":"2001","unstructured":"Friedberg, E. C. How nucleotide excision repair protects against cancer. Nature Rev. Cancer. 1, 22\u201333 (2001). Comprehensive review relating NER defects to cancer predisposition syndromes.","journal-title":"Nature Rev. Cancer."},{"key":"BFnrc1120_CR69","first-page":"3237","volume":"53","author":"J Bramson","year":"1993","unstructured":"Bramson, J. & Panasci, L. C. Effect of ERCC-1 overexpression on sensitivity of Chinese Hamster Ovary cells to DNA damaging agents. Cancer Res. 53, 3237\u20133240 (1993).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR70","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/nar\/22.15.3005","volume":"22","author":"F Larminat","year":"1994","unstructured":"Larminat, F. & Bohr, V. A. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res. 22, 3005\u20133010 (1994).","journal-title":"Nucleic Acids Res."},{"key":"BFnrc1120_CR71","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0006-2952(00)00441-X","volume":"60","author":"KV Ferry","year":"2000","unstructured":"Ferry, K. V., Hamilton, T. C. & Johnson, S. W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Biochem. Pharmacol. 60, 1305\u20131313 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc1120_CR72","first-page":"6152","volume":"55","author":"JE Cleaver","year":"1995","unstructured":"Cleaver, J. E., Charles, W. C., McDowell, M. L., Sadinski, W. J. & Mitchell, D. L. Overexpression of the XPA repair gene increases resistance to ultraviolet radiation in human cells by selective repair of DNA damage. Cancer Res. 55, 6152\u20136160 (1995).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR73","first-page":"764","volume":"61","author":"E Rosenberg","year":"2001","unstructured":"Rosenberg, E., Taher, M. M., Kuemmerle, N. B., Farnsworth, J. & Valerie, K. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res. 61, 764\u2013770 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR74","unstructured":"Reference deleted in proof."},{"key":"BFnrc1120_CR75","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0006-2952(01)00835-8","volume":"63","author":"JM Barret","year":"2002","unstructured":"Barret, J. M., Cadou, M. & Hill, B. T. Inhibition of nucleotide excision repair and sensitization of cells to DNA cross-linking anticancer agents by F 11782, a novel fluorinated epipodophylloid. Biochem. Pharmacol. 63, 251\u2013258 (2002). Example of a new drug that targets NER.","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc1120_CR76","first-page":"4529","volume":"59","author":"H Jiang","year":"1999","unstructured":"Jiang, H. & Yang, L. Y. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res. 59, 4529\u20134534 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc1120_CR77","unstructured":"Fact Sheet. Twelve major cancers. Sci. Am. 275, 92\u201398 (1996)."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc1120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1120","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc1120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:25:40Z","timestamp":1684455940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc1120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["BFnrc1120"],"URL":"https:\/\/doi.org\/10.1038\/nrc1120","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}